Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 3,331 | 378 | 2,906 |
| Samples | 717 | 118 | 586 |
| Peptides | 729 | 115 | 635 |
Function
SORBS2 · Sorbin and SH3 domain containing 2
Arg and c-Abl represent the mammalian members of the Abelson family of non-receptor protein-tyrosine kinases. They interact with the Arg/Abl binding proteins via the SH3 domains present in the carboxy end of the latter group of proteins. This gene encodes the sorbin and SH3 domain containing 2 protein. It has three C-terminal SH3 domains and an N-terminal sorbin homology (SoHo) domain that interacts with lipid raft proteins. The subcellular localization of this protein in epithelial and cardiac muscle cells suggests that it functions as an adapter protein to assemble signaling complexes in stress fibers, and that it is a potential link between Abl family kinases and the actin cytoskeleton. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
12 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000355634 | O94875-11 | 716 | 509 |
| ENST00000284776 | O94875 | 666 | 469 |
| ENST00000487836 | O94875-7 | 488 | 366 |
| ENST00000437304 | O94875-10 | 326 | 265 |
| ENST00000319471 | O94875-12 | 311 | 246 |
| ENST00000393528 | O94875-2 | 295 | 230 |
| ENST00000449407 | O94875-9 | 274 | 215 |
| ENST00000451974 | O94875-8 | 178 | 139 |
| ENST00000695409 | A0A8Q3WKK4* | 74 | 63 |
| ENST00000319454 | H7BXR3* | 1 | 1 |
| ENST00000421420 | C9JWC3* | 1 | 1 |
| ENST00000650145 | A0A3B3ITL8* | 1 | 1 |
Gene Properties
Recurrent Mutations
All 509 amino-acid changes on canonical ENST00000355634 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in SORBS2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in SORBS2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 8/42 19% | 37/612 6% |
| Glioblastoma | 5/98 5% | 0/0 0% |
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Melanoma | 18/210 9% | 80/1899 4% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Colorectal Carcinoma | 21/143 15% | 85/3239 3% |
| Other Solid Cancers | 3/94 3% | 45/1515 3% |
| Gastric Carcinoma | 5/74 7% | 45/1809 2% |
| Burkitts Lymphoma | 5/32 16% | 0/196 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 18/810 2% |
| Cervical Carcinoma | 0/35 0% | 9/422 2% |
| Mesothelioma | 3/62 5% | 1/165 1% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 21/1390 2% |
| Small Cell Lung Carcinoma | 0/9 0% | 11/752 1% |
| Hodgkins Lymphoma | 1/16 6% | 1/122 1% |
| Osteosarcoma | 2/45 4% | 1/166 1% |
| Bladder Carcinoma | 1/58 2% | 13/956 1% |
| Hepatocellular Carcinoma | 3/46 7% | 28/2210 1% |
| Esophageal Squamous Cell Carcinoma | 4/51 8% | 29/2550 1% |
| Plasma Cell Myeloma | 1/44 2% | 3/305 1% |
| Neuroendocrine Tumour | 3/154 2% | 5/577 1% |
| Head and Neck Carcinoma | 3/85 4% | 15/1574 1% |
| Esophageal Carcinoma | 0/23 0% | 8/769 1% |
| Ovarian Carcinoma | 0/109 0% | 11/998 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Biliary Tract Carcinoma | 1/54 2% | 7/950 1% |
| Other Sarcomas | 0/69 0% | 6/699 1% |
| Glioma | 0/52 0% | 17/2127 1% |
| Breast Carcinoma | 5/144 3% | 21/3264 1% |
Mutation Distribution
Where SORBS2 is mutated · all tissues, split by cell line vs tissue
How many mutations in SORBS2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 3,331 mutations in SORBS2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|